Resolve, To Assess the Feasibility of the Production of Insulin in Maine
Maine Legislature, Session 130, LD 1729
Committee Amendment CA_A_S508 (Senate)

COMfVtITTEE AMENDMENT" A "to S.P. 574, L.D. 1729, "Resolve, To Assess the 
Feasibility of the Production of Insulin in Maine" 
Amend the resolve by striking out the title and substituting the following: 
'Resolve, To Assess the Feasibility of the Production oflnsulin and Insulin Analogs in 
Maine' 
Amend the resolve by striking out everything after the title and inserting the following: 
'Sec. 1. Commission established. Resolved: That the Department of Health and 
Human Services shall convene a commission consisting of the following 12 members: 
1. The Commissioner of Health and Human Services or the commissioner's designee; 
2. A representative of the Department of Health and Human Services, Maine Center 
for Disease Control and Prevention; 
3. An individual involved in biomedical research; 
4. A representative of the Department of Professional and Financial Regulation, Maine 
Board of Pharmacy; 
5. A representative of the Department of Professional and Financial Regulation, 
Bureau of Insurance; 
6. A representative of the University of Maine System; 
7. A resident of the State receiving treatment for diabetes or a representative of an 
organization that represents or advocates for residents of the State receiving treatment for 
diabetes; 
8. Two physicians licensed to practice within the State having expertise in the 
treatment of diabetes and related complications; 
9. A research scientist having expertise in the synthesis • or production of drugs or 
biologics, including insulin and insulin analogs; 
10. A representative of hospitals and health care providers within the State; and 
COMMITTEE AMENDMENT 
ROS 
.<t\lll,ujlii(lt~!Ui 
COMMITTEE AMENDMENT" A 
"to S.P. 574, L.D. 1729 { 5 ''St, tJ J 
11. A representative of an organization that advocates for greater access to insulin and 
insulin analogs and that does not accept funding from an insulin or insulin analogs 
manufacturer. 
Sec. 2. Feasibility assessment. Resolved: That the commission established in 
section 1 shall assess the feasibility of producing insulin and insulin analogs in the State 
through the University of Maine System and other appropriate institutions or through a 
public-private partnership between the University of Maine System, other appropriate 
institutions and a licensed drug manufacturer. The commission shall also assess the 
feasibility of providing the insulin and insulin analogs produced to low-income residents 
of the State at low or no cost through hospitals, pharmacies and health care providers in the 
State or at a reduced cost on a means-tested basis. In its assessment, the commission shall 
consider various factors including: 
1. The number of low-income residents of the State who currently require insulin; 
2. The ability of the University of Maine System by itself, in partnership with another 
appropriate institution or through a public-private partnership with a licensed drug 
manufacturer to produce insulin and insulin analogs in an amount sufficient to fulfill the 
needs of low-income residents of the State who require insulin; 
3. Any long-term cost savings and revenue generation for the State and the University 
of Maine System; 
4. Any long-term cost savings and other benefits to low-income residents of the State 
who would receive insulin and insulin analogs at low or no cost; 
5. Any costs to the University of Maine System and to the State to produce and 
distribute insulin and insulin analogs, including additional administrative costs; 
6. State and federal regulatory or legal obstacles, including requirements for licensure, 
to the production and distribution of insulin and insulin analogs within the State by the 
University of Maine System or other appropriate institutions; 
7. Available alternative methods for providing insulin and insulin analogs to low-
income residents of the State at low or no cost; 
8. Options for capping copayments for insulin and insulin analogs provided through 
private insurers; 
9. The potential for the State to engage in volume purchasing of insulin and insulin 
analogs at reduced cost; 
10. The mechanisms by which the State could establish a program to distribute insulin 
and insulin analogs to residents of the State; 
11. Opportunities to establish an interstate compact with other New England states to 
reduce insulin and insulin analog costs in compact states; 
12. Opportunities to establish a public entity to manage the purchasing and distribution 
of insulin and insulin analogs with the possibility of eventual transition to a private entity; 
13. Opportunities to establish a model facility to affordably manufacture insulin and 
insulin analogs and to distribute insulin and insulin analogs to residents of the State; and 
COMMITTEE AMENDMENT 
COMMITTEE AMENDMENT "A "to S.P. 574, L.D. 1729 ( 'S-'5b7:)\ 
ROS 1 
--<ildbntut!tiiklli 2 
14. Opportunities to procure dedicated funding to support the manufacture of insulin 
and insulin analogs and the distribution of insulin and insulin analogs to residents of the 
State. 
The commission shall seek input from members of the Legislature when conducting 
the assessment required by this section. 
Sec. 3. Report. Resolved: That, by November 2, 2022, the commission established 
in section 1 shall provide a report to the Joint Standing Committee on Health and Human 
Services that includes its assessment under section 2 of the feasibility of manufacturing 
insulin and insulin analogs in the State and distributing such insulin and insulin analogs to 
low-income residents of the State at low or no cost and recommendations, including 
proposed legislation, for promoting insulin and insulin analogs manufacturing in the State 
through the University of Maine System or a public-private partnership. The joint standing 
committee may introduce legislation on the basis of the commission's report during the 
Amend the resolve by relettering or renumbering any nonconsecutive Part letter or 
section number to read consecutively. 
SUMMARY 
This amendment replaces the resolve and makes the following changes. It: 
1. Replaces the term "insulin" with "insulin and insulin analogs" throughout; 
2. Adds to the commission a representative of an organization that advocates for 
greater access to insulin and insulin analogs and that does not accept funding from an 
insulin or insulin analogs manufacturer; 
3. Adds the following factors to the feasibility assessment: 
A. Options for capping copayments for insulin and insulin analogs provided through 
private insurers; 
B. The potential for the State to engage in volume purchasing of insulin and insulin 
analogs at reduced cost; 
C. The mechanisms by which the State could establish a program to distribute insulin 
and insulin analogs to residents of the State; 
D. Opportunities to establish an interstate compact with other New England states to 
reduce insulin and insulin analog costs in compact states; 
E. Opportunities to establish a public entity to manage the purchasing and distribution 
of insulin and insulin analogs with the possibility of eventual transition to a private 
entity; 
F. Opportunities to establish a model facility to affordably manufacture insulin and 
insulin analogs and to distribute insulin and insulin analogs to Maine residents; and 
G. Opportunities to procure dedicated funding to support the manufacture of insulin 
and insulin analogs and the distribution of insulin and insulin analogs to Maine 
residents; and 
COMMITTEE AMENDMENT 
COMMITTEE AMENDMENT "A" to S.P. 574, L.D. 1729l Sr~ <SJ 
4. Changes from January 1, 2022 to November 2, 2022 the date the commission is 
required to submit the report to the Joint Standing Committee on Health and Human 
Services that includes an assessment of the feasibility of manufacturing insulin and insulin 
analogs in the State and distributing such insulin and insulin analogs to low-income 
residents of the State at low or no cost and recommendations, including proposed 
legislation, for promoting insulin and insulin analogs manufacturing in the State through 
the University of Maine System or a public-private partnership. 
FISCAL NOTE REQUIRED 
(See attached) 
COMMITTEE AMENDMENT 
Approved: 03/24/22 ;::!z,rae 
LD 1729 
LR 2008(02) 
Resolve, To Assess the Feasibility of the Production of Insulin in Maine 
Fiscal Detail and Notes 
Fiscal Note for Bill as Amended by Committee Amendment 'tt ( 'S-~()J 
Committee: Health and Human Services 
Fiscal Note Required: Yes 
Fiscal Note 
Minor cost increase - General Fund 
Minor cost increase - Other Special Revenue Funds 
Any additional costs to the Department of Health and Human Services to convene a commission to assess the 
feasibility of the production of insulin in Maine are expected to be minor and can be absorbed within existing 
budgeted resources. Additional costs to the University of Maine System, the Maine Board of Pharmacy and the 
Bureau of Insurance to have representatives serve on the commission are also expected to be minor and can be 
absorbed within existing budgeted resources. 
LR2008(02) - Fiscal Note - Page 1 of 1